ONC201: Stressing tumors to death

被引:18
|
作者
Greer, Yoshimi Endo [1 ]
Lipkowitz, Stanley [1 ]
机构
[1] NCI, Womens Malignancies Branch Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; APOPTOTIC PATHWAY; CANCER; TRAIL; THERAPY; MECHANISMS;
D O I
10.1126/scisignal.aad7955
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The small molecule ONC201 was identified in a screen for compounds that would induce expression of the gene encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in tumors and thus cause an autocrine- or paracrine-induced death in tumor cells. Two Research Articles in this issue of Science Signaling by Ishizawa et al. and Kline et al. describe how ONC201 can also trigger cytotoxicity by inducing a stress response. The mechanisms of the stress response induced differ between hematological malignancies and solid tumors, highlighting the complexity of ONC201-induced toxicity and raising intriguing issues of tissue-specific pathways activated by the drug.
引用
收藏
页数:2
相关论文
共 50 条
  • [1] ONC201 TARGETING IN DIPG
    Abuarqoub, Alqassem
    McAnulty, Tatiana
    Amiel, Eyal
    Stafford, James
    NEURO-ONCOLOGY, 2021, 23 : 24 - 25
  • [2] Combination Radiation Therapy and Imipridone ONC201 for the Treatment of Solid Tumors
    Jhawar, S. R.
    Goyal, S.
    Thandoni, A.
    Wu, H.
    Hassan, S.
    Schiff, D. S.
    Allen, J.
    Stogniew, M.
    Tarapore, R.
    Stein, M.
    Bertino, J.
    Haffty, B. G., Jr.
    Zloza, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E598 - E598
  • [3] MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206
    Prabhu, Varun
    Cuoco, Caroline
    Jung, Jinkyu
    Morrow, Sara
    Kawakibi, Abed Rahman
    Willette, Blair
    Day, Marilyn
    Anantharaman, Lakshmi
    Charter, Neil
    Rucker, Joseph
    Doranz, Benjamin
    Basken, Joel
    Stogniew, Martin
    Gilbert, Mark
    Free, R.
    Sibley, David
    Allen, Joshua
    NEURO-ONCOLOGY, 2020, 22 : 68 - 68
  • [4] ONC201 shows promise in AML treatment
    Edwards, Holly
    Ge, Yubin
    CELL CYCLE, 2018, 17 (03) : 277 - 277
  • [5] REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
    Stafford, James
    Abuarqoub, Alqassem
    Mcanulty, Tatiana
    Possemato, Richard
    Amiel, Eyal
    Snuderl, Matija
    NEURO-ONCOLOGY, 2021, 23 : 26 - 26
  • [6] First-in-human trial of ONC201 in patients with refractory solid tumors.
    Stein, Mark N.
    Chan, Nancy
    Silk, Ann W.
    Fang, Bruno
    Kaufman, Howard
    Haffty, Bruce George
    Saunders, Tracie
    Najmi, Saltanat
    Zheng, Ling
    Stogniew, Martin
    Allen, Joshua E.
    Oster, Wolfgang
    Bertino, Joseph R.
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
    Arrillaga-Romany, Isabel
    Kurz, Sylvia
    Tarapore, Rohinton S.
    Sumrall, Ashley
    Butowski, Nicholas
    Harrison, Rebecca
    de Groot, John
    Chi, Andrew
    Shonka, Nicole
    Umemura, Yoshie
    Odia, Yazmin
    Mehta, Minesh
    Nghiemphu, Phioanh
    Cloughesy, Timothy
    Taylor, Lynne
    Graber, Jerome
    Kilburn, Lindsay
    Dixit, Karan
    Lu, Guangrong
    Allen, Joshua
    Batchelor, Tracy
    Lassman, Andrew
    Wen, Patrick
    NEURO-ONCOLOGY, 2020, 22 : 50 - 51
  • [8] Role of Dopamine Receptors in the Anticancer Activity of ONC201
    Kline, Christina Leah B.
    Ralff, Marie D.
    Lulla, Amriti R.
    Wagner, Jessica M.
    Abbosh, Phillip H.
    Dicker, David T.
    Allen, Joshua E.
    El-Deiry, Wafik S.
    NEOPLASIA, 2018, 20 (01): : 80 - 91
  • [9] TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
    Sridharan, Sreepradha
    Harmanci, Arif
    Sharma, Ajay
    Lai, Yanlai
    Kennis, Bridget
    Dobson, Tara
    Swaminathan, Jyothishmathi
    Haltom, Amanda
    Khatua, Soumen
    Tarapore, Rohinton
    Allen, Joshua
    Cheng, Donghang
    Zaky, Wafik
    Gopalakrishnan, Vidya
    NEURO-ONCOLOGY, 2020, 22 : 298 - 298
  • [10] TRAIL inducing small molecule ONC201 prevents intestinal tumors in FAP mouse model
    Rao, Chinthalapally, V
    Madka, Venkateshwar
    Zhang, Yuting
    Pathuri, Gopal
    Panneerselvam, Janani
    Stratton, Nicole
    Finnberg, Niklas K.
    Safran, Howard P.
    Fox, Jennifer
    Sei, Shizuko
    Glaze, Elizabeth R.
    Shoemaker, Robert
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2020, 80 (16)